The tumor necrosis factor (TNF) inhibitors (etanercept, infliximab, adalimumab, certolizumab pegol and golimumab) that decrease the inflammatory response; T-cell costimulatory blocker (abatacept) that interferes with the interactions between antigen-presenting cells and T cells; the B cell depleting agent (rituximab) that leads to a rapid and sustained depletion of circulating B cells, reducing RA progression and the interleukin receptor inhibitors for interleukin-6 (IL-6) (tocilizumab and sarilumab) and interleukin-1 (IL-1) (anakinra) that decrease inflammation and RA progression [6,31]. Here, IL6 is linked to rheumatoid arthritis.